MDxHealth Provides Q3-2020 Business Update - Seite 2

• SelectMDx for Prostate Cancer test has been included in the 2020 National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection
• Q3-2020 revenue of $4.5 million, while down 6% from $4.7 million in Q3-2019 due to the pandemic, reflects improvement in our revenue cycle management and cash collections during the year
• ConfirmMDx units down 17% compared to Q3-2019 due to the pandemic; Q3-2020 units increased 14% sequentially compared to Q2-2020
• SelectMDx units down 24% compared to Q3-2019 due to the pandemic; Q3-2020 units increased 57% sequentially compared to Q2-2020
• Operating cash use of $4.7 million for the quarter resulting in ending cash balance of $21.4 million

Summary of billable test volume by product

Products	Quarter Ended September 30,
	2020	2019	% Change
ConfirmMDx	3,579	4,305	(17)%
SelectMDx	3,267	4,273	(24)%

Subsequent events

      ·On October 20, 2020, MDxHealth and Kreos Capital executed an amendment to the 2019 loan facility, extending the interest-only period from 12 months to 18 months. As a result of this amendment, repayment of principal has been extended from November 2020 to May 2021. As part of the amendment, the Company agreed to increase the end-of-loan fee by €67,500 (approx. $80,000) as well as to provide for €180,000 of the €9 million loan to be convertible into shares of MDxHealth at a 25% premium to the 30-day volume weighted average price immediately prior to signing the amendment. If exercised, this amount will be reduced from the principal amount due under the loan agreement.

Outlook for the remainder of 2020 into 2021

The Company remains confident in its menu of commercial stage products to provide urologists with actionable results providing a clear clinical pathway to accurately identify clinically significant prostate cancer, while optimizing patient selection for the use of invasive procedures. We believe this clinical pathway, with SelectMDx guiding cancer detection in a pre-biopsy setting and ConfirmMDx in a post-biopsy setting, will continue to drive adoption and utilization of our menu.